Biotechnology company
Appears in 1 story · Last updated Oct 31, 2026
Developing DAX-044; will fund and run the Phase 1 trial
Japanese drugmaker Astellas Pharma now holds an exclusive option to license DAX-044, a preclinical cancer therapy from Melbourne-based Audax Biosciences. The deal is worth up to $1.34 billion, including $285 million in upfront and option exercise payments and up to $1.05 billion in milestones, before royalties.
Updated Oct 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
